---
title: Asthma/COPD
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 20
date: 2023-03-30
---

- Short-Acting Beta 2 Agonists (SABAs)
  - Salbutamol (Albuterol)
    - Can cause hypokalemia with muscle weakness, arrhythmias, and tremors
    - EKG changes, palpitations, and HA may occur
    - Albuterol
      - Nebulizer: 2.5-5mg q20mins for 4 doses, then 2.5-10mg q1-4hrs
      - MDI (Ventolin HFA, Proventil HFA, ProAir HFA): 4-8 puffs q30mins up to 4hrs, then every 1-4hrs PRN
  - Levalbterol MDI (Xopenex, Xopenex HFA)
  - Pirbuterol MDI (MaxAir autohaler)
  - Terbutaline
  - SEs: Tremor (7%), tachycardia, anxiety
    - Hypokalemia, angina, tachyarrhythmia
- Long-Acting Beta 2 Agonists (LABAs)

    - Not recommended without ICS in asthma due to increased mortality
  - Salmeterol DPI (Serevent Diskus, Aeromax)
  - Formoterol DPI (Foradil Aerolizer)
  - Oxis
  - Serovent
  - Onbrex
  - SE: Headache (17%), Tremor (8%)
    - Hypertension, Rash, dizziness, hyperglycemia
- Inhaled Corticosteroid (ICSs)
  - Beclomethasone MDI (QVAR)
  - Budesonide DPI (Pulmicort Flexhaler)
  - Flunisolide MDI (Aerospan)
  - Fluticasone Propionate MDI (Flovent HFA)
  - Fluticasone Furoate DPI (Arnuity Ellipta)
  - Mometasone DPI (Asmanex Twisthaler)
  - Triamcinolone
- Oral Corticosteroid
  - Methylprednisolone
    - Asthma: 32-64 mg/day PO in 1-2 doses
      - 40-80 mg/day IV in 1-2 doses
      - Reserve IV for NPO or severe in the ICU
      - Depo-Medrol 160mg IM at discharge equal to 8 days PO taper
  - Prednisolone
  - Prednisone
    - Asthma: 40-80 mg/day PO in 1-2 doses
      - Give until PEF is 70% predicted
      - 7–10-day courses do not need to be tapered
    - SE: Elevated Uric Acid, Increase or decrease INR w/Warfarin
- Antimuscarinics (SAMA/LAMA)
  - Short-Acting Anticholinergics (SAMAs)
    - Ipratropium Bromide
      - Nebulizer: Must use with albuterol
      - MDI (Atrovent HFA): 4-8 puffs PRN every 2-4hrs
      - Better tolerated than LAMAs
    - SE: Bitter taste (20%), Xerostomia
      - Urinary retention, mydriasis
  - Long-Acting Anticholinergics (LAMAs)
    - Tiotropium Bromide (Spiriva Handihaler)
      - SE: Xerostomia (16%), Constipation
        - Rash, myalgia, dysphonia
    - Bretaris
    - SEEbri
    - Incruse Ellipta
- Combos
  - SAMA/SABA
    - Ipratropium + Albuterol (Combivent Respimat)
  - LAMA/LABA
    - Vilanterol/umeclidinium (Anoro)
  - LABA/ICS
    - Budesonide/Formoterol MDI (Symbicort)
    - Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (Trelegy Ellipta)
    - Fluticasone/Salmeterol MDI (Advair HFA)
    - Fluticasone/Salmeterol DPO (Advair Diskus)
    - Fluticasone Furoate/Vilanterol (Breo Ellipta)
    - Ipratropium Bromide/Salbutamol (Combivent)
    - Mometasone/formoterol (Durela hfa)
  - LAMA/LABA/ICS
    - Fluticasone/Umeclidinium/Vilanterol (Trelegy Ellipta)
- Other
  - Methylxanthines
    - Theophylline
      - SE: Caffeine-like, MAT
        - Toxicity: vomiting, hypokalemia, hyperglycemia, seizures, tachycardia, ventricular arrhythmias
  - Eicosanoid Inhibition
    - Leukotriene Antagonists
      - Montelukast (Singulair): 10 mg QD tablet
    - Arachidonate 5-lipoxygenase Inhibitors
      - Zileuton (Zyflo CR): 1200mg BID tablet
    - Thromboxane Receptor Antagonists
    - Non-xanthine PDE4 Inhibitors
    - Zafirlukast (Accolate): 20mg BID tablet
      - AST/ALT ≥3x normal in 3%, monitor monthly for 3 months when initiating
  - Mast Cell Stabilizers
    - Cromolyn Sodium Nebulizer solution
  - IgE Inhibitor
    - Omalizumab (Xolair): 150mg injection
  - PDE-4 Inhibitors
    - Roflumilast (Daliresp): 500 ug tablet QD
